title: A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth.
abstract: Endogenous angiogenesis inhibitors have shown promise in preclinical trials, but clinical use has been hindered by low half-life in circulation and high production costs. Here, we describe a strategy that targets the angiostatin receptor angiomotin (Amot) by DNA vaccination. The vaccination procedure generated antibodies that detected Amot on the endothelial cell surface. Purified Ig bound to the endothelial cell membrane and inhibited endothelial cell migration. In vivo, DNA vaccination blocked angiogenesis in the matrigel plug assay and prevented growth of transplanted tumors for up to 150 days. We further demonstrate that a combination of DNA vaccines encoding Amot and the extracellular and transmembrane domains of the human EGF receptor 2 (Her-2)/neu oncogene inhibited breast cancer progression and impaired tumor vascularization in Her-2/neu transgenic mice. No toxicity or impairment of normal blood vessels could be detected. This work shows that DNA vaccination targeting Amot may be used to mimic the effect of angiostatin.
authors.affiliation: Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, SE171 76 Stockholm, Sweden.
authors.forename: Lars
authors.initials: L
authors.lastname: Holmgren
authors.forename: Elena
authors.initials: E
authors.lastname: Ambrosino
authors.forename: Olivier
authors.initials: O
authors.lastname: Birot
authors.forename: Carl
authors.initials: C
authors.lastname: Tullus
authors.forename: Niina
authors.initials: N
authors.lastname: Veitonmäki
authors.forename: Tetyana
authors.initials: T
authors.lastname: Levchenko
authors.forename: Lena-Maria
authors.initials: LM
authors.lastname: Carlson
authors.forename: Piero
authors.initials: P
authors.lastname: Musiani
authors.forename: Manuela
authors.initials: M
authors.lastname: Iezzi
authors.forename: Claudia
authors.initials: C
authors.lastname: Curcio
authors.forename: Guido
authors.initials: G
authors.lastname: Forni
authors.forename: Federica
authors.initials: F
authors.lastname: Cavallo
authors.forename: Rolf
authors.initials: R
authors.lastname: Kiessling
mesh_terms: D000091082:Angiomotins; D000818:Animals; D000906:Antibodies / Q000378:metabolism; D002460:Cell Line; D002465:Cell Movement / Q000502:physiology; D042783:Endothelial Cells / Q000166:cytology / Q000378:metabolism; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics / Q000276:immunology*; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D008840:Microfilament Proteins; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology*; D009389:Neovascularization, Pathologic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D019444:Vaccines, DNA
chemical_list: D000091082:Angiomotins; D000906:Antibodies; D036341:Intercellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D008840:Microfilament Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins; D019444:Vaccines, DNA; C423985:AMOT protein, human